Drugs / AdreView
Regulatory milestones approvals, filings & regulatory actions · 2 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ADREVIEW | — | 2013-03-20 | fda.gov ↗ |
| Approved | US (FDA) | ADREVIEW | — | 2008-09-19 | fda.gov ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 4 | NCT01868841 Comparator | Dec 2013 → Sep 2014 | cardiomyopathy, heart failure | Timothy M. Bateman | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AdreView | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01868841 ↗ |
| Known as | 123I-mIBG | “10 millicurie of AdreView (123I-mIBG)” NCT01868841 ↗ |